| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/27/2011 | CN101496802B Use of arylpiperazine derivatives in preparing medicament for treating ache |
| 04/27/2011 | CN101474372B Method for preparing Chinese medicine for treating children's wind-heat cold |
| 04/27/2011 | CN101448498B Compositions of r(+) and s(-) pramipexole and methods of using the same |
| 04/27/2011 | CN101411700B Use of 5,7,4'-trihydroxy flavanone or derivative thereof for analgesia |
| 04/27/2011 | CN101306198B NR2B recombinant adenovirus vaccine |
| 04/27/2011 | CN101288702B Mongolian medicine for treating sleep disorder |
| 04/27/2011 | CN101284828B Cycloheptapyridine compounds, preparation method thereof, use and pharmaceutical compositions containing the compounds |
| 04/27/2011 | CN101274927B Photochemical reaction preparation for quaternary ring compound and use of the quaternary ring compound |
| 04/27/2011 | CN101143192B Therapeutic gastrodia extracts |
| 04/27/2011 | CN101103020B Cgrp receptor antagonists |
| 04/27/2011 | CN101077407B Medicine for treating depression caused by simple emotion factor |
| 04/27/2011 | CN100998313B Production method of ginseng culture root extraction with high content of ginsenoside and its use |
| 04/26/2011 | US7932392 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 04/26/2011 | US7932371 Tick octopamine receptor nucleic acid molecules |
| 04/26/2011 | US7932350 Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes |
| 04/26/2011 | US7932271 Heterocyclic methyl sulfone derivative |
| 04/26/2011 | US7932259 Pyrrolo[2,3-d]pyrimidine derivatives substituted with a cyclic amino group |
| 04/26/2011 | US7932257 Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors |
| 04/26/2011 | US7932249 Olanzapine pamoate dihydrate |
| 04/26/2011 | US7932248 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity |
| 04/26/2011 | US7932234 Bispecific oligonucleotide for the treatment of CNS malignancies |
| 04/26/2011 | US7931022 Method and apparatus for dispensing inhalator medicament |
| 04/26/2011 | CA2584060C Use of agomelatin to produce medications for treating generalized anxiety disorder |
| 04/26/2011 | CA2562581C Electronic atomization cigarette |
| 04/26/2011 | CA2546970C Imidazole derivatives, processes for preparing them and their uses |
| 04/26/2011 | CA2500952C Neurologically-active compounds |
| 04/26/2011 | CA2495879C Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders |
| 04/26/2011 | CA2491506C N-aryl diazaspiracyclic compounds and methods of preparation and use thereof |
| 04/26/2011 | CA2479133C 2-4-diaminopyrimidine derivatives |
| 04/26/2011 | CA2468038C Preparation of trans-fused 3,3a,8,12b-tetrahydro-2h-dibenzo[3,4:6,7]cyclohepta[1,2-b]furan derivatives |
| 04/26/2011 | CA2462416C Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-ht2b receptor antagonist |
| 04/26/2011 | CA2460145C Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 04/26/2011 | CA2447999C Caspase inhibitors and uses thereof |
| 04/26/2011 | CA2446461C Substituted cyclohexane-1,4-diamine derivatives |
| 04/26/2011 | CA2446112C A method for regulating immune function in primates using the foxp3 protein |
| 04/26/2011 | CA2439480C Carbamate compounds for use in preventing or treating psychotic disorders |
| 04/26/2011 | CA2430707C 8-{4-[3-(5-fluoro-1h-indol-3-yl)propyl]-piperazin-1-yl}-2-methyl-4h-benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine d2 receptor and the serotonin reuptake site |
| 04/26/2011 | CA2423628C Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them |
| 04/26/2011 | CA2420410C Pharmaceutical compositions for headache, migraine, nausea and emesis |
| 04/26/2011 | CA2420231C Antibodies to human il-1.beta. |
| 04/26/2011 | CA2415397C Use of strains of parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer |
| 04/26/2011 | CA2414008C Gabapentin analogues for sleep disorders |
| 04/26/2011 | CA2402099C Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment |
| 04/26/2011 | CA2319093C Sea cucumber carotenoid lipid fraction products and methods of use |
| 04/21/2011 | WO2011047374A1 Methods of treating tauopathies |
| 04/21/2011 | WO2011047341A2 Treatment of suicidal ideation or behavior using inhibitors of nicotinic acetylcholine receptors |
| 04/21/2011 | WO2011047315A1 Subsitituted benzimidazoles |
| 04/21/2011 | WO2011047277A2 Release of agents from cells |
| 04/21/2011 | WO2011047262A2 Dual variable domain immunoglobulins and uses thereof |
| 04/21/2011 | WO2011047173A2 Pharmaceutical compositions for oral administration |
| 04/21/2011 | WO2011047143A1 Compositions and methods for mild sedation, anxiolysis and analgesia in the procedural setting |
| 04/21/2011 | WO2011046997A1 Cgrp receptor antagonists |
| 04/21/2011 | WO2011046954A1 Hematopoietic growth factor mimetic small molecule compounds and their uses |
| 04/21/2011 | WO2011046622A2 Mutant low-density lipoprotein receptor related protein with increased binding to alzheimer amyloid-beta peptide |
| 04/21/2011 | WO2011046451A1 Maintaining or increasing cognitive development |
| 04/21/2011 | WO2011046411A2 Chestnut extracts with neuro cellular protective activity and acetylcholinesterase inhibiting activity, and use thereof |
| 04/21/2011 | WO2011046221A1 INTERFERON-α MODULATOR |
| 04/21/2011 | WO2011045945A1 ANTIBODY RECOGNIZING TURN STRUCTURE IN AMYLOID β |
| 04/21/2011 | WO2011045769A2 Anti-misuse solid oral dosage form provided having a modified specific release profile |
| 04/21/2011 | WO2011045353A1 Indole and azaindole modulators of the alpha 7 nachr |
| 04/21/2011 | WO2011045270A1 Monohydrate of pardoprunox |
| 04/21/2011 | WO2011045267A1 Polymorphs of pardoprunox |
| 04/21/2011 | WO2011045258A1 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor |
| 04/21/2011 | WO2011025121A3 Composition for clearing hangovers using hot-spring water |
| 04/21/2011 | WO2011025120A3 Composition for clearing hangovers and composition for restoring liver function using hot-spring water |
| 04/21/2011 | WO2011023713A3 Salidroside for the pharmacological treatment of bulimia nervosa and binge eating disorder (bed) |
| 04/21/2011 | WO2011020030A9 Methods and compositions to prevent addiction |
| 04/21/2011 | WO2011015349A3 Methods for enhancing the cognitive function |
| 04/21/2011 | WO2011014973A3 Conformationally constrained, fully synthetic macrocyclic compounds |
| 04/21/2011 | WO2011012896A3 Spirocyclic amide derivatives |
| 04/21/2011 | WO2010150281A3 Novel azabicyclohexanes |
| 04/21/2011 | WO2010144721A3 Model systems and treatment regimes for treatment of neurological disease |
| 04/21/2011 | WO2010141712A9 Modulation of kcnq potassium channel activity for treatment of psychiatric disorders and the symptoms thereof |
| 04/21/2011 | WO2010137890A3 Composition for improving the viability and proliferation ability of stem cells |
| 04/21/2011 | WO2010135493A3 Alzheimer's disease imaging agents |
| 04/21/2011 | WO2008080988A3 Cyclopentanone derivatives, method of synthesis and uses thereof |
| 04/21/2011 | US20110092669 Synthesis of cyclosporin analogs |
| 04/21/2011 | US20110092600 Pharmaceutical compositions comprising aminocyclohexane derivatives |
| 04/21/2011 | US20110092594 Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions |
| 04/21/2011 | US20110092591 Phenyl-prenyl derivatives, of marine and synthetic origin, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
| 04/21/2011 | US20110092589 Treatment of Inflammatory Conditions and Diseases with Metal-Thiols |
| 04/21/2011 | US20110092588 Lactone formulations and method of use |
| 04/21/2011 | US20110092583 Oral Dosage Form Of Tetrahydrocannabinol And A Method Of Avoiding And/Or Suppressing Hepatic First Pass Metabolism Via Targeted Chylomicron/Lipoprotein Delivery |
| 04/21/2011 | US20110092571 Compositions and methods for sirna inhibition of icam-1 |
| 04/21/2011 | US20110092565 Method of treating neurodegenerative disease |
| 04/21/2011 | US20110092561 Benzoisoindole derivatives for the treatment of pain |
| 04/21/2011 | US20110092559 Pyrrole and pyrazole daao inhibitors |
| 04/21/2011 | US20110092554 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders |
| 04/21/2011 | US20110092545 Compounds, Compositions and Methods for Stabilizing Transthyretin and Inhibiting Transthyretin Misfolding |
| 04/21/2011 | US20110092542 Methods for treating spinal cord injury with a compound that inhibits a ncca-atp channel |
| 04/21/2011 | US20110092541 Novel compositions for preventing and/or treating degenerative disorders of the central nervous system |
| 04/21/2011 | US20110092540 Substituted n-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands |
| 04/21/2011 | US20110092539 Indane derivatives as ampa receptor modulators |
| 04/21/2011 | US20110092538 Compounds and methods for kinase modulation, and indications therefor |
| 04/21/2011 | US20110092535 Novel Epilepsy Treatment |
| 04/21/2011 | US20110092525 Gabaa receptor modulators |
| 04/21/2011 | US20110092519 5,7-disubstituted thiazolo[4,5-d]pyrimidines as chemokine inhibitors |
| 04/21/2011 | US20110092517 Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases |
| 04/21/2011 | US20110092516 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressin-dependent diseases |
| 04/21/2011 | US20110092513 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases |